|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
CA2195622C
(en)
|
1991-02-27 |
1999-08-17 |
Frank J. Urban |
Process for preparing trans-piperidine-2,5-dicarboxylates
|
|
CA2192725C
(en)
|
1995-12-28 |
2004-04-20 |
Kenji Tsujihara |
Camptothecin derivatives
|
|
WO2003000657A1
(en)
|
2001-06-20 |
2003-01-03 |
Daiichi Pharmaceutical Co., Ltd. |
Diamine derivatives
|
|
ES2605443T3
(es)
|
2003-11-06 |
2017-03-14 |
Seattle Genetics, Inc. |
Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
|
|
US20050142133A1
(en)
|
2003-12-03 |
2005-06-30 |
Xencor, Inc. |
Optimized proteins that target the epidermal growth factor receptor
|
|
WO2009011285A1
(ja)
|
2007-07-13 |
2009-01-22 |
Taisho Pharmaceutical Co., Ltd. |
ヘテロアリールベンゼン化合物
|
|
JP5639039B2
(ja)
|
2008-04-11 |
2014-12-10 |
メリマック ファーマシューティカルズ インコーポレーティッド |
ヒト血清アルブミンリンカーおよびそのコンジュゲート
|
|
KR20110044905A
(ko)
|
2008-08-15 |
2011-05-02 |
메리맥 파마슈티컬즈, 인크. |
치료제에 대한 세포의 반응을 예측하는 방법 및 시스템
|
|
CN102282168A
(zh)
|
2008-11-18 |
2011-12-14 |
梅里麦克制药股份有限公司 |
人血清白蛋白接头以及其结合物
|
|
WO2010127284A2
(en)
|
2009-05-01 |
2010-11-04 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
|
TW201109438A
(en)
|
2009-07-29 |
2011-03-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
MX2012002651A
(es)
|
2009-09-01 |
2012-05-22 |
Abbott Lab |
Inmunoglobulinas de dominio variable doble y usos de las mismas.
|
|
CA2775573A1
(en)
*
|
2009-10-09 |
2011-04-14 |
Merck Sharp & Dohme Corp. |
Generation, characterization and uses thereof of anti-her 3 antibodies
|
|
US8658175B2
(en)
|
2009-10-28 |
2014-02-25 |
Abbvie Biotherapeutics Inc. |
Anti-EGFR antibodies and their uses
|
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
US9051370B2
(en)
|
2010-08-10 |
2015-06-09 |
Glycotope Gmbh |
Humanized EGFR antibodies
|
|
UY33707A
(es)
|
2010-11-04 |
2012-05-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
US20120195900A1
(en)
|
2010-12-22 |
2012-08-02 |
Abbott Laboratories |
Tri-variable domain binding proteins and uses thereof
|
|
CA2828099A1
(en)
|
2011-02-24 |
2012-08-30 |
Merrimack Pharmaceuticals, Inc. |
Combination therapies comprising anti-erbb3 agents
|
|
EP2815765A1
(en)
|
2011-03-15 |
2014-12-24 |
Merrimack Pharmaceuticals, Inc. |
Overcoming resistance to ERBB pathway inhibitors
|
|
TW201333039A
(zh)
|
2011-12-30 |
2013-08-16 |
Abbvie Inc |
雙可變域免疫球蛋白及其用途
|
|
CA2866612C
(en)
|
2012-03-08 |
2018-01-16 |
Halozyme, Inc. |
Conditionally active ph-dependent cetuximab variant anti-epidermal growth factor receptor antibodies and method of use thereof
|
|
PE20150605A1
(es)
|
2012-04-27 |
2015-05-28 |
Cytomx Therapeutics Inc |
Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico
|
|
WO2013170263A2
(en)
|
2012-05-11 |
2013-11-14 |
Merrimack Pharmaceuticals, Inc. |
Dosage and administration of bispecific scfv conjugates in combination with anti-cancer therapeutics
|
|
ES2690315T3
(es)
|
2012-06-15 |
2018-11-20 |
Mitsubishi Tanabe Pharma Corporation |
Compuestos de imidazol y triazol como inhibidores de DGAT-1
|
|
KR20150058236A
(ko)
|
2012-08-20 |
2015-05-28 |
글리크닉 인코포레이티드 |
항원 결합 및 다가 fc 감마 수용체 결합 활성을 가진 분자
|
|
US9345766B2
(en)
|
2012-08-30 |
2016-05-24 |
Merrimack Pharmaceuticals, Inc. |
Combination therapies comprising anti-ERBB3 agents
|
|
US20150239977A1
(en)
|
2012-09-27 |
2015-08-27 |
Massachusetts Institute Of Technology |
Cd20- and egfr-binding proteins with enhanced stability
|
|
US10195288B2
(en)
|
2012-10-11 |
2019-02-05 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate
|
|
EP2910573B1
(en)
|
2012-10-19 |
2020-02-19 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate produced by binding through linker having hydrophilic structure
|
|
EP2948475A2
(en)
|
2013-01-23 |
2015-12-02 |
AbbVie Inc. |
Methods and compositions for modulating an immune response
|
|
MY186864A
(en)
|
2013-03-12 |
2021-08-26 |
Biocon Ltd |
Fusion immunomodulatory proteins and methods for making same
|
|
EP2970485A1
(en)
|
2013-03-15 |
2016-01-20 |
Merck Patent GmbH |
Tetravalent bispecific antibodies
|
|
US10239951B2
(en)
|
2013-05-08 |
2019-03-26 |
Zymeworks Inc. |
Bispecific HER2 and HER3 antigen binding constructs
|
|
US9879081B2
(en)
|
2013-06-25 |
2018-01-30 |
Samsung Electronics Co., Ltd. |
Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
|
|
JP6693872B2
(ja)
|
2013-07-25 |
2020-05-13 |
シトムクス セラピューティクス，インコーポレイティド |
多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
|
|
WO2015038984A2
(en)
|
2013-09-12 |
2015-03-19 |
Halozyme, Inc. |
Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
|
|
US9540440B2
(en)
|
2013-10-30 |
2017-01-10 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
|
AP2016009222A0
(en)
|
2013-11-04 |
2016-05-31 |
Glenmark Pharmaceuticals Sa |
Production of t cell retargeting hetero-dimeric immunoglobulins
|
|
EP3068892A4
(en)
|
2013-11-13 |
2017-05-31 |
Zymeworks Inc. |
Monovalent antigen binding constructs targeting egfr and/or her2 and uses thereof
|
|
SG10201902571VA
(en)
|
2013-12-25 |
2019-04-29 |
Daiichi Sankyo Co Ltd |
Anti-trop2 antibody-drug conjugate
|
|
SG11201603960XA
(en)
|
2014-01-31 |
2016-07-28 |
Daiichi Sankyo Co Ltd |
Anti-her2 antibody-drug conjugate
|
|
EP3107557B1
(en)
*
|
2014-02-17 |
2021-06-09 |
Seagen Inc. |
Hydrophilic antibody-drug conjugates
|
|
TWI871999B
(zh)
|
2014-04-10 |
2025-02-01 |
日商第一三共股份有限公司 |
抗her3抗體-藥物結合物
|
|
US11185594B2
(en)
*
|
2014-04-10 |
2021-11-30 |
Daiichi Sankyo Company, Limited |
(Anti-HER2 antibody)-drug conjugate
|
|
WO2015189477A1
(en)
|
2014-06-13 |
2015-12-17 |
Tenboron Oy |
Conjugates comprising an anti-egfr1 antibody
|
|
CA2944085C
(en)
|
2014-09-16 |
2018-04-10 |
Ease Charm Limited |
Anti-egfr antibody and uses of same
|
|
CN104403004B
(zh)
|
2014-11-24 |
2017-10-13 |
苏州丁孚靶点生物技术有限公司 |
抗体‑干扰素异二聚体的制备和用途
|
|
US12428483B2
(en)
*
|
2014-12-22 |
2025-09-30 |
Systimmune, Inc. |
Bispecific tetravalent antibodies and methods of making and using thereof
|
|
US10717783B2
(en)
|
2014-12-22 |
2020-07-21 |
Zeren Gao |
Bispecific tetravalent antibodies and methods of making and using thereof
|
|
CN105820248A
(zh)
|
2015-01-07 |
2016-08-03 |
上海张江生物技术有限公司 |
一种新型抗egfr单克隆抗体的制备方法及应用
|
|
KR101770559B1
(ko)
|
2015-04-23 |
2017-08-24 |
신일제약주식회사 |
EGFR에 특이적으로 결합하는 Fab 단편
|
|
WO2016196682A1
(en)
|
2015-06-01 |
2016-12-08 |
Immunexcite, Inc. |
β-1,6-GLUCAN CETUXIMAB ANTIBODY CONJUGATES
|
|
CN107709356A
(zh)
|
2015-06-26 |
2018-02-16 |
南加利福尼亚大学 |
用于肿瘤特异性活化的掩蔽嵌合抗原受体t细胞
|
|
CA2994969A1
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
|
|
EP3400248A4
(en)
|
2016-01-10 |
2019-09-04 |
Sorrento Therapeutics, Inc. |
IMPROVED SAFETY FOR THE TREATMENT OF CANCER WITH GLYCOSYLATED CHIMERIC ANTIBODY AGAINST EGFR
|
|
SG10202008909VA
(en)
|
2016-03-24 |
2020-10-29 |
Bayer Pharma AG |
Prodrugs of cytotoxic active agents having enzymatically cleavable groups
|
|
CN109563166B
(zh)
|
2016-04-28 |
2022-12-20 |
拜奥穆尼克斯制药 |
靶向egfr和her2的双特异性抗体
|
|
CN116333130A
(zh)
|
2016-05-24 |
2023-06-27 |
英斯梅德股份有限公司 |
抗体及其制备方法
|
|
WO2018026742A1
(en)
|
2016-08-01 |
2018-02-08 |
Askgene Pharma Inc. |
Novel antibody-albumin-drug conjugates (aadc) and methods for using them
|
|
CN110352068A
(zh)
|
2016-12-02 |
2019-10-18 |
南加利福尼亚大学 |
合成的免疫受体及其使用方法
|
|
JPWO2018110515A1
(ja)
|
2016-12-12 |
2019-10-24 |
第一三共株式会社 |
抗体−薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ
|
|
US12059472B2
(en)
|
2016-12-21 |
2024-08-13 |
Bayer Aktiengesellschaft |
Prodrugs of cytotoxic active agents having enzymatically cleavable groups
|
|
GB201705686D0
(en)
|
2017-04-07 |
2017-05-24 |
Centauri Therapeutics Ltd |
Novel compounds and therapeutic uses thereof
|
|
CN108948195B
(zh)
|
2017-05-23 |
2022-05-31 |
胡毅 |
一种抗egfr/pd-l1双靶向抗体、其制备方法及用途
|
|
CN108948206B
(zh)
|
2017-05-23 |
2022-08-23 |
赵磊 |
一种抗egfr/pd-1双靶向抗体、其制备方法及用途
|
|
US20200140547A1
(en)
|
2017-05-26 |
2020-05-07 |
The Johns Hopkins University |
Multifunctional antibody-ligand traps to modulate immune tolerance
|
|
WO2018228442A1
(en)
|
2017-06-14 |
2018-12-20 |
Dingfu Biotarget Co., Ltd. |
Proteinaceous heterodimer and use thereof
|
|
AU2018288029B2
(en)
|
2017-06-19 |
2021-12-23 |
Systimmune, Inc. |
Antibody-drug conjugate having acidic self-stabilization junction
|
|
CN109306010B
(zh)
|
2017-07-26 |
2022-07-19 |
石家庄以岭药业股份有限公司 |
表皮生长因子受体抗体及其用途
|
|
KR20210029298A
(ko)
|
2017-08-16 |
2021-03-15 |
드래곤플라이 쎄라퓨틱스, 인크. |
Nkg2d, cd16, 및 egfr, ccr4 또는 pd-l1에 결합하는 단백질
|
|
CN109106951A
(zh)
*
|
2017-08-18 |
2019-01-01 |
四川百利药业有限责任公司 |
一种喜树碱-抗体偶联物
|
|
SG11202001514XA
(en)
|
2017-08-31 |
2020-03-30 |
Daiichi Sankyo Co Ltd |
Novel method for producing antibody-drug conjugate
|
|
EP3677589B1
(en)
|
2017-08-31 |
2025-11-26 |
Daiichi Sankyo Company, Limited |
Improved method for producing antibody-drug conjugate
|
|
EP3457139B1
(en)
|
2017-09-19 |
2026-08-05 |
Promise Proteomics |
Antibody-like peptides for quantifying therapeutic antibodies
|
|
CN119264274A
(zh)
|
2017-10-12 |
2025-01-07 |
免疫苏醒公司 |
Vegfr-抗体轻链融合蛋白
|
|
CN108220244A
(zh)
|
2018-01-18 |
2018-06-29 |
东北农业大学 |
一种含重组人表皮生长因子受体抗体基因的cho细胞株、筛选方法及其生产工艺
|
|
US10654944B2
(en)
|
2018-04-10 |
2020-05-19 |
Y-Biologics Inc. |
Cell engaging binding molecules
|
|
WO2019232323A1
(en)
|
2018-05-31 |
2019-12-05 |
Board Of Regents, The University Of Texas System |
Bi-specific antibodies and use thereof
|
|
MX2020014290A
(es)
|
2018-06-22 |
2021-08-05 |
Cugene Inc |
Farmacos bioactivables a base de citoquinas y métodos de usos de los mismos.
|
|
WO2020006486A1
(en)
|
2018-06-29 |
2020-01-02 |
Krystal Biotech, Inc. |
Compositions and methods for antibody delivery
|
|
UA130338C2
(uk)
|
2018-09-26 |
2026-01-28 |
Джянгсу Хенгруй Медісін Ко., Лтд. |
Кон'югат ліганд-лікарський засіб аналога ексатекану, спосіб його отримання та його застосування
|
|
JP7408646B2
(ja)
|
2018-09-30 |
2024-01-05 |
ジエンス ハンソー ファーマスーティカル グループ カンパニー リミテッド |
抗－ｂ７ｈ３抗体－エキサテカンアナログコンジュゲート及びその医薬用途
|
|
GB201816554D0
(en)
|
2018-10-10 |
2018-11-28 |
Centauri Therapeutics Ltd |
Novel compounds and therapeutic uses thereof
|
|
GB201816553D0
(en)
|
2018-10-10 |
2018-11-28 |
Centauri Therapeutics Ltd |
Novel compounds and therapeutic uses thereof
|
|
BR112021008486A2
(pt)
|
2018-11-01 |
2021-10-26 |
Shandong New Time Pharmaceutical Co., Ltd |
Anticorpo biespecífico e seu uso
|
|
CN111196855B
(zh)
|
2018-11-19 |
2022-11-15 |
三生国健药业（上海）股份有限公司 |
抗egfr/pd-1双特异性抗体
|
|
JP2022510218A
(ja)
|
2018-11-30 |
2022-01-26 |
メモリアル スローン ケタリング キャンサー センター |
ヘテロ二量体四価特異性抗体およびこれらの使用
|
|
US12344646B2
(en)
|
2018-12-13 |
2025-07-01 |
Bang DING |
Antibody-TNF α fusion protein and its preparation and applications
|
|
EP3898681A2
(en)
|
2018-12-17 |
2021-10-27 |
Alligator Bioscience AB |
Polypeptides
|
|
KR102991359B1
(ko)
|
2018-12-28 |
2026-07-16 |
쿄와 기린 가부시키가이샤 |
TfR에 결합하는 이중 특이적 항체
|
|
CN111689980A
(zh)
|
2019-05-26 |
2020-09-22 |
四川百利药业有限责任公司 |
一种喜树碱药物及其抗体偶联物
|
|
AU2020288275A1
(en)
|
2019-06-06 |
2022-02-03 |
Jiangsu Hansoh Pharmaceutical Group Co., Ltd. |
Anti-B7-H4 antibody–drug conjugate and medicinal use thereof
|
|
WO2020259258A1
(zh)
*
|
2019-06-28 |
2020-12-30 |
上海复旦张江生物医药股份有限公司 |
一种抗体偶联药物、其中间体、制备方法及应用
|
|
CN110256583B
(zh)
|
2019-07-11 |
2022-05-20 |
中国科学院生物物理研究所 |
一种il-2突变体与抗体的融合蛋白及其应用
|
|
MX2022001027A
(es)
|
2019-07-26 |
2022-04-18 |
Abl Bio Inc |
Anticuerpo biespecifico anti-egfr/anti-4-1bb y uso del mismo.
|
|
CN110669132B
(zh)
|
2019-08-19 |
2023-03-31 |
天津大学前沿技术研究院 |
一种提高IgG1抗体产量的方法
|
|
CN112125915A
(zh)
*
|
2019-09-18 |
2020-12-25 |
四川百利药业有限责任公司 |
一种喜树碱衍生物及其偶联物
|
|
CA3151237A1
(en)
|
2019-09-19 |
2021-03-25 |
Ramesh Baliga |
Multimeric antibodies with enhanced selectivity for cells with high target density
|
|
AU2020402006A1
(en)
|
2019-12-12 |
2022-07-07 |
Jiangsu Hengrui Medicine Co., Ltd. |
Anti-claudin antibody-drug conjugate and pharmaceutical use thereof
|
|
BR112022011632A2
(pt)
|
2019-12-16 |
2022-10-04 |
Jiangsu Hengrui Medicine Co |
Conjugado análogo de anticorpo exatecano anti-cea e uso farmacêutico do mesmo
|
|
US20230101735A1
(en)
|
2020-01-22 |
2023-03-30 |
Jiangsu Hengrui Medicine Co., Ltd. |
Anti-trop-2 antidody-exatecan analog conjugate and medical use thereof
|
|
WO2021173612A1
(en)
|
2020-02-26 |
2021-09-02 |
Sorrento Therapeutics, Inc. |
Activatable antigen binding proteins with universal masking moieties
|
|
CN113388631B
(zh)
|
2020-03-12 |
2022-08-09 |
天津大学 |
一种高产IgG1的重组菌及构建方法
|
|
WO2021190480A1
(zh)
|
2020-03-24 |
2021-09-30 |
上海翰森生物医药科技有限公司 |
抗体-药物偶联物及其医药用途
|
|
WO2021190586A1
(zh)
|
2020-03-25 |
2021-09-30 |
江苏恒瑞医药股份有限公司 |
B7h3抗体-依喜替康类似物偶联物及其医药用途
|
|
CN115103691B
(zh)
|
2020-03-25 |
2025-01-24 |
苏州盛迪亚生物医药有限公司 |
一种含抗体药物偶联物的药物组合物及其用途
|
|
CA3175048A1
(en)
|
2020-03-25 |
2021-09-30 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Preparation method for antibody medicament conjugate
|
|
MX2022011808A
(es)
|
2020-03-25 |
2022-12-06 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Conjugado de anticuerpo anti-psma-analogo de exatecan y uso medico del mismo.
|
|
WO2021190564A1
(zh)
|
2020-03-26 |
2021-09-30 |
上海翰森生物医药科技有限公司 |
抗体药物偶联物及其医药用途
|
|
US10994021B1
(en)
|
2020-04-11 |
2021-05-04 |
Bliss Biopharmaceutical (Hangzhou) Co., Ltd. |
Tetravalent antibody-drug conjugates and use thereof
|
|
CN113563473A
(zh)
|
2020-04-29 |
2021-10-29 |
三生国健药业（上海）股份有限公司 |
四价双特异性抗体、其制备方法和用途
|
|
CN113754771A
(zh)
|
2020-06-02 |
2021-12-07 |
三生国健药业（上海）股份有限公司 |
一种抗pdl1×egfr的双特异性抗体
|
|
BR112022024930A2
(pt)
*
|
2020-06-08 |
2022-12-27 |
Baili Bio Chengdu Pharmaceutical Co Ltd |
Fármaco de camptotecina possuindo unidade de conexão hidrofílica de alta estabilidade e conjugado do mesmo
|
|
CN111848806B
(zh)
|
2020-06-18 |
2022-06-10 |
广东安普泽生物医药股份有限公司 |
Egfr-cd3双功能抗体及其应用
|
|
EP4190812A4
(en)
|
2020-07-27 |
2024-09-04 |
Tuojie Biotech (Shanghai) Co., Ltd. |
ANTI-CD79B ANTIBODY-DRUG CONJUGATE, ITS PREPARATION METHOD AND ITS PHARMACEUTICAL USE
|
|
NZ781239A
(en)
|
2020-09-15 |
2024-11-29 |
Systimmune Inc |
A camptothecin drug and its antibody conjugate thereof
|
|
AU2021354827A1
(en)
|
2020-09-30 |
2023-06-01 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Pharmaceutical composition comprising antibody-drug conjugate, and use of pharmaceutical composition
|
|
EP4227310A4
(en)
|
2020-10-12 |
2024-11-06 |
Sichuan Baili Pharmaceutical Co. Ltd. |
CAMPTOTHECIN DERIVATIVE AND LIGAND-DRUG CONJUGATE THEREOF
|
|
WO2022078259A1
(zh)
*
|
2020-10-12 |
2022-04-21 |
四川百利药业有限责任公司 |
一种氘代的喜树碱衍生物及其抗体药物偶联物
|
|
CN116133694B
(zh)
|
2020-10-14 |
2026-03-06 |
苏州盛迪亚生物医药有限公司 |
抗her3抗体和抗her3抗体药物偶联物及其医药用途
|
|
WO2022099762A1
(zh)
|
2020-11-12 |
2022-05-19 |
博瑞生物医药（苏州）股份有限公司 |
一种抗体偶联物中间体及其制备方法
|
|
CN114569739A
(zh)
|
2020-12-01 |
2022-06-03 |
正大天晴药业集团股份有限公司 |
抗体药物偶联物
|
|
AU2022216696A1
(en)
|
2021-02-05 |
2023-08-17 |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
Camptothecin compound, preparation method therefor, and application thereof
|
|
CN114409562B
(zh)
|
2021-02-08 |
2024-08-02 |
四川百利药业有限责任公司 |
一种ca4衍生物及其配体-药物偶联物
|
|
WO2022194257A1
(zh)
|
2021-03-17 |
2022-09-22 |
江苏恒瑞医药股份有限公司 |
一种喜树碱衍生物的制备方法
|
|
CN115192732B
(zh)
|
2021-04-01 |
2025-02-18 |
成都百利多特生物药业有限责任公司 |
一种dna毒性二聚体化合物及其偶联物
|
|
TW202302649A
(zh)
|
2021-04-26 |
2023-01-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
抗ｎｅｃｔｉｎ－４抗體和抗ｎｅｃｔｉｎ－４抗體－藥物偶聯物及其醫藥用途
|
|
CN113816969B
(zh)
|
2021-04-30 |
2024-01-16 |
联宁（苏州）生物制药有限公司 |
依喜替康类化合物、其抗体药物偶联物及其应用
|
|
AU2022269073A1
(en)
|
2021-05-07 |
2023-11-23 |
ALX Oncology Inc. |
Exatecan derivatives and antibody-drug conjugates thereof
|
|
TW202317199A
(zh)
|
2021-06-25 |
2023-05-01 |
大陸商同宜醫藥（蘇州）有限公司 |
配體藥物偶聯物及其應用
|
|
CA3224492A1
(en)
|
2021-07-19 |
2023-01-26 |
Xiaojun Han |
Immunoconjugates and methods
|
|
JP2024536798A
(ja)
|
2021-09-23 |
2024-10-08 |
シャンハイ ハンソー バイオメディカル カンパニー リミテッド |
抗体薬物コンジュゲート並びにその製造方法及び医薬用途
|
|
CN115850291B
(zh)
|
2021-09-24 |
2024-11-15 |
石药集团巨石生物制药有限公司 |
喜树碱衍生物及其用途
|
|
US11814394B2
(en)
|
2021-11-16 |
2023-11-14 |
Genequantum Healthcare (Suzhou) Co., Ltd. |
Exatecan derivatives, linker-payloads, and conjugates and thereof
|
|
KR20240142405A
(ko)
|
2021-11-17 |
2024-09-30 |
씨에스피씨 메가리스 바이오파마슈티칼 씨오., 엘티디. |
항체-약물 복합체 및 그의 용도
|
|
CN116212044A
(zh)
|
2021-12-03 |
2023-06-06 |
成都百利多特生物药业有限责任公司 |
抗人Trop2抗体-喜树碱类药物偶联物及其医药用途
|
|
CN118414339A
(zh)
|
2021-12-16 |
2024-07-30 |
迈威(上海)生物科技股份有限公司 |
一种喜树碱类化合物及其偶联物
|
|
MX2024008036A
(es)
|
2021-12-28 |
2024-07-15 |
Beigene Switzerland Gmbh |
Conjugados de anticuerpo y farmaco.
|